Bioasis Technologies Stock Fundamentals
BIOAF Stock | USD 0.0004 0.0003 300.00% |
biOasis Technologies fundamentals help investors to digest information that contributes to BiOasis Technologies' financial success or failures. It also enables traders to predict the movement of BiOasis Pink Sheet. The fundamental analysis module provides a way to measure BiOasis Technologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BiOasis Technologies pink sheet.
BiOasis |
biOasis Technologies Company Shares Outstanding Analysis
BiOasis Technologies' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current BiOasis Technologies Shares Outstanding | 79.41 M |
Most of BiOasis Technologies' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, biOasis Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition |
Based on the latest financial disclosure, biOasis Technologies has 79.41 M of shares currently outstending. This is 56.01% lower than that of the Biotechnology sector and 25.68% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 86.11% higher than that of the company.
biOasis Technologies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BiOasis Technologies's current stock value. Our valuation model uses many indicators to compare BiOasis Technologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BiOasis Technologies competition to find correlations between indicators driving BiOasis Technologies's intrinsic value. More Info.biOasis Technologies is rated third in return on asset category among its peers. It is rated second in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BiOasis Technologies' earnings, one of the primary drivers of an investment's value.BiOasis Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BiOasis Technologies' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BiOasis Technologies could also be used in its relative valuation, which is a method of valuing BiOasis Technologies by comparing valuation metrics of similar companies.BiOasis Technologies is currently under evaluation in shares outstanding category among its peers.
BiOasis Fundamentals
Return On Asset | -0.81 | |||
Operating Margin | (11.41) % | |||
Current Valuation | 6 M | |||
Shares Outstanding | 79.41 M | |||
Shares Owned By Insiders | 2.05 % | |||
Price To Earning | 13.82 X | |||
Price To Book | 53.47 X | |||
Price To Sales | 26.52 X | |||
Revenue | 37.73 K | |||
Gross Profit | (1.15 M) | |||
EBITDA | (3.54 M) | |||
Net Income | (2.96 M) | |||
Cash And Equivalents | 764.97 K | |||
Cash Per Share | 0.01 X | |||
Total Debt | 401.76 K | |||
Debt To Equity | 0.31 % | |||
Current Ratio | 0.38 X | |||
Book Value Per Share | (0.03) X | |||
Cash Flow From Operations | (3.64 M) | |||
Earnings Per Share | (0.03) X | |||
Target Price | 0.58 | |||
Number Of Employees | 23 | |||
Beta | 0.39 | |||
Market Capitalization | 2.13 M | |||
Total Asset | 2.27 M | |||
Retained Earnings | (18.69 M) | |||
Working Capital | 437 K | |||
Current Asset | 874 K | |||
Current Liabilities | 437 K | |||
Z Score | -11.5 | |||
Net Asset | 2.27 M |
About BiOasis Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze biOasis Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BiOasis Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of biOasis Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut. Bioasis Technologies operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in BiOasis Pink Sheet
BiOasis Technologies financial ratios help investors to determine whether BiOasis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BiOasis with respect to the benefits of owning BiOasis Technologies security.